The "U.S. Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, ADC), By Synthesis, By Drug, By Workflow, By Application, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering.
The U.S. active pharmaceutical ingredients CDMO market was valued at USD 25.28 billion in 2024 and is projected to reach USD 33.86 billion by 2030, growing at a CAGR of 5.1% from 2025 to 2030
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the U.S. active pharmaceutical ingredients CDMO market report based on product, synthesis, drug, workflow, and application.
This growth is driven by rising demand for advanced pharmaceutical manufacturing services to support the development of innovative drugs and therapies. In addition, increasing investments in biologics and high-potency APIs drive market expansion. The growing prevalence of chronic diseases and the need for efficient, scalable production solutions also contribute to the market's momentum.
Key drivers supporting this market growth include technological advancements in process chemistry and manufacturing automation, which improve yield, reduce waste, and enhance product quality. Regulatory support encouraging outsourcing to specialized CDMOs is vital, as these organizations help ensure compliance with stringent FDA and international standards.
The increasing focus on personalized medicine and novel therapies drives demand for small-batch, complex API manufacturing, areas where CDMOs excel due to their flexibility and expertise. Growing collaborations between pharmaceutical firms and CDMOs also foster innovation and accelerate time-to-market, enabling companies to meet better evolving patient better needs.
The market presents significant opportunities, especially in developing biologics, gene therapies, and cell therapies requiring highly specialized API manufacturing. The trend toward continuous manufacturing and flow chemistry offers avenues for CDMOs to improve efficiency and scalability while reducing costs and environmental impact.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Companies Featured
- Thermo Fisher Scientific Inc.
- Novo Group (Catalent, Inc.)
- Cambrex Corporation
- Piramal Pharma Limited
- Corden Pharma
- Siegfried Holding AG
- Seqens North America
- SK pharmteco Inc.
- Noramco.
- BSP Pharmaceuticals
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 80 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $25.28 Billion |
| Forecasted Market Value (USD) by 2030 | $33.86 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | United States |
Key Topics Covered:
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definition
1.3. Information Procurement
1.4. Information Analysis
1.5. Market Formulation and Data Visualization
1.6. Data Validation and Publishing
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Active Pharmaceutical Ingredients CDMO Market Variables, Trends and Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.2.3. Industry Challenge
3.3. Industry Analysis Tools
3.3.1. Porter's Analysis
3.3.2. PESTEL Analysis
Chapter 4. U.S. Active Pharmaceutical Ingredients CDMO Market: Product Estimates and Trend Analysis
4.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Product: Key Takeaways
4.2. Product Movement Analysis and Market Share, 2024 and 2030
4.3. Market Estimates and Forecasts, By Product, 2018 - 2030 (USD Million)
4.3.1. Traditional Active Pharmaceutical Ingredient
4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Highly Potent Active Pharmaceutical Ingredient
4.3.3. Antibody Drug Conjugate (ADC)
4.3.4. Other
Chapter 5. U.S. Active Pharmaceutical Ingredients CDMO Market: Synthesis Estimates and Trend Analysis
5.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Synthesis: Key Takeaways
5.2. Synthesis Movement Analysis and Market Share, 2024 and 2030
5.3. Market Estimates and Forecasts, By Synthesis, 2018 - 2030 (USD Million)
5.3.1. Synthetic
5.3.2. Biotech
Chapter 6. U.S. Active Pharmaceutical Ingredients CDMO Market: Drug Estimates and Trend Analysis
6.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Drug: Key Takeaways
6.2. Drug Movement Analysis and Market Share, 2024 and 2030
6.3. Market Estimates and Forecasts, By Drug, 2018 - 2030 (USD Million)
6.3.1. Innovative
6.3.2. Generic
Chapter 7. U.S. Active Pharmaceutical Ingredients CDMO Market: Workflow Estimates and Trend Analysis
7.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Workflow: Key Takeaways
7.2. Workflow Movement Analysis and Market Share, 2024 and 2030
7.3. Market Estimates and Forecasts, By Workflow, 2018 - 2030 (USD Million)
7.3.1. Clinical
7.3.2. Commercial
Chapter 8. U.S. Active Pharmaceutical Ingredients CDMO Market: Application Estimates and Trend Analysis
8.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Application: Key Takeaways
8.2. Application Movement Analysis and Market Share, 2024 and 2030
8.3. Market Estimates and Forecasts, By Application, 2018 - 2030 (USD Million)
8.3.1. Oncology
8.3.2. Hormonal
8.3.3. Glaucoma
8.3.4. Cardiovascular disease
8.3.5. Diabetes
8.3.6. Others
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Company Market Positioning
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Portfolio
9.4.4. Recent Developments/ Strategic Initiatives
For more information about this report visit https://www.researchandmarkets.com/r/heobjn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250815360481/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900